Spots Global Cancer Trial Database for tumor suppressor gene 2 (tusc2)
Every month we try and update this database with for tumor suppressor gene 2 (tusc2) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | NCT04486833 | Carcinoma, Non-... | quaratusugene o... osimertinib Platinum-Based ... | 18 Years - | Genprex, Inc. | |
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | NCT05062980 | Non Small Cell ... | quaratusugene o... pembrolizumab docetaxel ramucirumab Investigator's ... | 18 Years - | Genprex, Inc. | |
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | NCT05062980 | Non Small Cell ... | quaratusugene o... pembrolizumab docetaxel ramucirumab Investigator's ... | 18 Years - | Genprex, Inc. | |
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | NCT05703971 | Small Cell Lung... | quaratusugene o... atezolizumab | 18 Years - | Genprex, Inc. | |
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | NCT04486833 | Carcinoma, Non-... | quaratusugene o... osimertinib Platinum-Based ... | 18 Years - | Genprex, Inc. |